WFH, Sanofi and Sobi for Armenia: Unprecedented Commitment to Build the Humanitarian Aid Program
Scott Williams, VP and Head, Global Public Affairs at Sanofi, shared an honoring post on LinkedIn:
”In 2014, the World Federation of Hemophilia (WFH) put out a call to action to join them and build their Humanitarian Aid (HA) Program into a more sustainable and predictable solution. Sanofi, along with Sobi, responded with an unprecedented commitment – to provide 1 billion IUs of factor therapy over 10 years. This commitment drove other companies to collaborate with the WFH HA Program and together, we empowered the WFH to provide treatment not only for life-saving surgeries but also for acute bleeds and prophylaxis in children.
I have just returned from a Humanitarian Aid visit with the World Federation of Hemophilia to Armenia. It is with humility that I share a look into 5 extraordinary days together.
It was so impactful to see the before and after progress that’s been made over the past 10+ years in Armenia. We saw a strong hemophilia treatment center and integrated multi-disciplinary care team, access to factor therapy, ability to have prophylaxis treatment at home, impactful local patient organization (NMO), and more. Meeting and hearing the stories of patients and families whose lives have been forever transformed truly puts the “human” in the humanitarian program. It is a powerful reminder of the good that can be achieved when we work together with a shared purpose.
At Sanofi, we are working as a committed industry partner with stakeholders across the bleeding disorders community to drive forward comprehensive, patient-centric solutions that go Beyond the Bleed to meaningfully advance the care paradigm. Envisioning a future beyond the bleed lies at the heart of our mission.
I will never be the same after the visit to Armenia with the WFH. The tears, hope, smiles, determination, and perseverance of children and family members living with hemophilia ensured that I will continue to be a deeply committed Rare Ambassador.”
More encouraging stories featured in Hemostasis Today.
-
Oct 28, 2025, 14:27Maha Othman on 10-Year Anniversary of the CanVECTOR Research Network!
-
Oct 28, 2025, 14:00Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
-
Oct 28, 2025, 13:31Laurent Bertoletti Invites You to The INNOVTE and GITA Joined Meeting on Hormones and Thrombosis
-
Oct 28, 2025, 12:28Courtney Lawrence: Honored to Team Up with BET on Blood at AABB 2025
-
Oct 27, 2025, 19:45Benedikt Lorenz on Liver Failure and Coagulation – Myths, Traps, and Bad Habits
-
Oct 28, 2025, 13:09Gregory Piazza on CORONA-VTE Network Analysis
-
Oct 27, 2025, 18:42Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
-
Oct 27, 2025, 13:30Fabrice Cognasse: When Platelets Meet Artificial Intelligence!
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 15:10David McIntosh: Making Measurable Progress – Towards a World in Which No-one Ever Dies from Lack of a Vital Plasma-Derived Medicine
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation